Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount
about
Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotateFrom preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patientsCurrent Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.177Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation.In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.HDR brachytherapy decreases proliferation rate and cellular progression of a radioresistant human squamous cell carcinoma in vitro.Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
P2860
Q36484229-C8AF0149-4E88-491A-819E-1DC824D305B8Q36755148-F0B8EF79-7DDB-4EA0-8570-CCA517F7FFB7Q37103342-6369DA40-8B0F-4610-AD0D-6977E126602BQ37731335-9DD0018A-B4DE-4AD6-AA87-67DB90936EA1Q38612027-A103331A-B33D-47B8-B350-22FE6B80AD05Q38696739-BD9DD863-A3E6-41A8-B3B0-2A0FD927A7F2Q38925590-75644694-8AC7-4694-8481-C3B9DF9344DBQ48284639-E2A51216-DC19-44EA-BD28-0861BAF39E1AQ55098217-D29E00CF-2DAF-4724-93BF-0311BA9DE5B4
P2860
Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Therapeutic application of CCK ...... e, activity and peptide amount
@ast
Therapeutic application of CCK ...... e, activity and peptide amount
@en
type
label
Therapeutic application of CCK ...... e, activity and peptide amount
@ast
Therapeutic application of CCK ...... e, activity and peptide amount
@en
prefLabel
Therapeutic application of CCK ...... e, activity and peptide amount
@ast
Therapeutic application of CCK ...... e, activity and peptide amount
@en
P2093
P2860
P1433
P1476
Therapeutic application of CCK ...... e, activity and peptide amount
@en
P2093
Erik de Blois
Ho Sze Chan
Marion de Jong
Mark W Konijnenberg
Marleen Melis
Petra Kolenc-Peitl
Wout A P Breeman
P2860
P2888
P356
10.1186/S13550-014-0047-1
P577
2014-08-30T00:00:00Z
P5875
P6179
1021248857